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Prophylaxis and Aspergillosis — Has the Principle Been Proven?
Ben E. De Pauw, M.D., and J. Peter Donnelly, Ph.D.
Invasive fungal diseases contribute substantially 
to death and illness associated with the prolonged, 
profound neutropenia resulting from intensive 
chemotherapy for hematologic cancers and from 
myeloablation for allogeneic hematopoietic stem-
cell transplantation. In addition, the development 
of graft-versus-host disease (GVHD) puts trans-
plant recipients at risk for infection for several 
weeks or months after engraftment.1 Given the 
high mortality associated with invasive fungal dis-
eases and our inability to recognize active cases 
reliably, it is not surprising that prophylaxis is 
perceived as a sensible therapeutic approach.
More than a decade ago, f luconazole was 
shown to be effective for preventing candida in-
fection.2 However, aspergillus species and other 
molds are not affected by this drug. Itraconazole 
has a spectrum of activity that includes aspergil-
lus species, but its use is limited by its erratic 
uptake in the body. Although the bioavailability 
of itraconazole is substantially improved with an 
oral solution, compliance and the propensity of 
the drug to interact with other agents are not.3 
The pathophysiology of invasive aspergillosis dif-
fers fundamentally from that of invasive candidi-
asis. Colonization of the mucosal membranes by 
candida precedes invasive disease, whereas asper-
gillus and other molds are contracted through 
the respiratory tract. Since there appears to be a 
positive correlation between efficacy and ade-
quate serum levels of itraconazole, it is tempting 
to assume that the antiaspergillus effect will be 
exerted primarily through systemic antifungal 
activity.4
The arrival of the new azole drug, posacona-
zole, was most welcome, since it not only is active 
in vitro against a wide range of yeasts (including 
candida species) and molds (including aspergil-
lus species, Zygomycetes, and fusarium species) 
but also appears to have an acceptable adverse-
event profile and is well tolerated. In this issue 
of the Journal, two controlled trials that were de-
signed to evaluate the prophylactic use of posa-
conazole are reported.5,6
One study, by Cornely et al., was a prospective, 
randomized, trial involving evaluators who were 
unaware of the treatment assignments and pa-
tients who were undergoing chemotherapy for 
acute leukemia or myelodysplastic syndromes. 
Posaconazole was compared with either flucona-
zole or itraconazole for the prevention of inva-
sive fungal disease.5 Prophylaxis was started with 
the first cycle of chemotherapy and was con-
tinued until recovery from neutropenia and com-
plete remission, until the occurrence of an in-
vasive fungal disease, or for up to 12 weeks, 
whichever came first. The incidences of proven 
and probable invasive fungal diseases were sig-
nificantly lower in the posaconazole group (2%) 
than in the f luconazole or itraconazole group 
(8%). There were also fewer cases of invasive as-
pergillosis after posaconazole prophylaxis (1%) 
than after f luconazole or itraconazole prophy-
laxis (7%).
The other study, by Ullmann et al., was a ran-
domized, double-blind trial of oral posaconazole 
or oral fluconazole as prophylaxis against inva-
sive fungal disease in hematopoietic stem-cell 
transplant recipients who were also receiving im-
munosuppressive therapy for GVHD.6 The pri-
mary end point was the incidence of proven or 
probable invasive fungal disease within 16 weeks 
after randomization. Posaconazole and flucona-
zole appeared to be equally efficacious in prevent-
ing all invasive fungal diseases (incidence, 5.3% 
and 9.0%, respectively), but posaconazole pre-
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vented more cases of proven or probable invasive 
aspergillosis (2.3%) than did fluconazole (7.0%). 
There were fewer deaths in the posaconazole 
group, and the drug was well tolerated and rela-
tively safe.
Both studies aimed to address efficacy: Does 
posaconazole work as prophylaxis in these two 
groups of patients? The answer is yes. One may 
quibble about the details of the studies. For in-
stance, why is it that the GVHD study by Ullmann 
et al. was double-blind and placebo-controlled 
but the study of neutropenia by Cornely et al. 
was not? There is also the curious observation by 
Cornely et al. that most cases of probable asper-
gillosis were based on a positive test for aspergil-
lus galactomannan antigen, not necessarily a 
positive culture or compatible histopathological 
findings. Remove these probable cases, and the 
advantage for posaconazole vanishes. It would be 
useful to know more about these cases and also 
whether there were similar cases for which the 
galactomannan test was negative in the posacona-
zole group, since concentrations of the antigen are 
affected by antifungal drugs that are active against 
mold.7 Although this was not stated explicitly, we 
assume that patients who were unable to take 
oral medication were excluded from the GVHD 
trial by Ullmann et al., because posaconazole can 
be given only orally. If this was indeed true, there 
may have been an unintentional selection of less-
sick patients, which might explain the rather low 
incidence of invasive aspergillosis in the flucon-
azole group. Neither study reported whether the 
ability to eat a fatty diet, to help drug absorption, 
or compliance was a prerequisite for inclusion, 
and the serum concentrations of the study drug 
were not noted. This information is important, 
since one wonders whether clinical success was 
achieved mainly in patients with adequate levels 
of the drug.
How generalizable are these results, and how 
effective will a strategy of posaconazole prophy-
laxis actually prove to be? In our center, we do 
not use primary prophylaxis at all for patients 
with GVHD or with prolonged neutropenia, pre-
ferring to rely on an integrated-care plan that in-
volves twice-weekly screening for galactomannan 
and a low threshold for ordering computed to-
mography of the chest to detect abnormal pulmo-
nary signs, exactly as reported by Maertens et al.8 
Only patients with pulmonary abnormalities con-
sistent with those due to invasive fungal disease, 
or probably due to such disease, are treated.
We use this treatment strategy because the 
overall incidence of invasive aspergillosis in our 
center is low, about 4.5%. Were we to use posa-
conazole therapy, the number of patients who 
would need to be treated to prevent one fungal 
infection (the number needed to treat) would be 
approximately 22, not 16 as reported by Cornely 
et al. There is the rub. McQuay and Moore9 posed 
four questions that need to be considered before 
adopting prophylaxis. First, would the event we 
are trying to prevent (i.e., invasive fungal disease) 
be difficult to treat if it occurred? Given the avail-
ability of voriconazole and liposomal amphoteri-
cin B, the answer would be no, provided we de-
tected the invasive fungal disease sufficiently early. 
Second, is invasive fungal disease a serious event? 
The answer is a clear yes. Third, is prophylaxis 
safe and tolerated well enough (i.e., are there 
few adverse effects)? The results of the studies by 
Ullmann et al. and Cornely et al. suggest that 
the answer is yes. Fourth, is the prophylaxis ef-
fective (i.e., is the number needed to treat rela-
tively low, such as <20)? The answer for our cen-
ter is no. However, for a number needed to treat 
of 16, as in the study of neutropenia by Cornely 
et al., the answer would be yes — so the decision 
in favor of prophylaxis hinges on the first ques-
tion about how difficult the event would be to 
treat. The answer would be different for centers 
vigilantly pursuing a preemptive approach and 
for centers that do not have the facilities or the 
means to do so. Centers treating patients with 
GVHD are not relieved from the dilemma either: 
Should the centers offer prophylaxis to approxi-
mately 27 at-risk patients in order to prevent 
the development of invasive aspergillosis in 1, 
or should no action be taken until invasive asper-
gillosis is suspected? Whether to use prophylaxis 
at all remains a choice that is pragmatic and de-
pends on factors other than the drug in question.
The scientific community now has the results 
of two phase 3 studies of posaconazole prophy-
laxis to ponder, without the drug having first 
won recognition as the primary therapy for inva-
sive aspergillosis. With posaconazole, the man-
agement of aspergillosis among high-risk patients 
has only become more puzzling: posaconazole 
appears to be the drug of choice for prophylaxis, 
whereas voriconazole remains the preferred treat-
ment for proven or probable aspergillosis,10 leav-
ing caspofungin and liposomal amphotericin B 
as the options for empirical therapy.11,12 This is 
the unfortunate consequence of mixing efficacy 
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studies that should explore the options and lim-
itations of a drug with strategic trials that, ide-
ally, should assess the appropriate moment to 
administer a drug with an established efficacy.
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Treatment of Uterine Fibroids — Is Surgery Obsolete?
Togas Tulandi, M.D., M.H.C.M.
In the early 1990s, Jacques H. Ravina first applied 
the technique of embolization of uterine arteries 
to treat uterine fibroids in women at high risk for 
complications during surgery1 in an effort to con-
trol uterine bleeding. Embolization was then ex-
panded for the treatment of patients who were 
undergoing myomectomy in order to decrease 
intraoperative bleeding. In 1993, Ravina and col-
leagues started using uterine-artery embolization 
as a primary treatment for uterine fibroids.
Today, interventional radiologists worldwide 
perform uterine-artery embolization. Most of 
them embolize the uterine arteries bilaterally and 
not only the branch supplying blood to a particu-
lar fibroid (Fig. 1). In observational studies, em-
bolization has been followed by a significant re-
duction in uterine volume, a decrease in excessive 
uterine bleeding, a low rate of subsequent hyster-
ectomy, and a high rate of sustained symptom 
control (up to 80%) 5 years after the procedure.2‑4 
However, comparisons of uterine-artery emboli-
zation with other treatments on the basis of ob-
servational data are limited by the inherent dif-
ferences in women who are referred for one 
treatment instead of another.
In this issue of the Journal, Moss et al., writing 
for the Randomized Trial of Embolization versus 
Surgical Treatment for Fibroids (REST) Investiga-
tors,5 report on the results of a randomized, mul-
ticenter trial comparing uterine-artery emboli-
zation with abdominal surgery in women with 
symptomatic uterine fibroids. The investigators 
randomly assigned 106 women to undergo em-
bolization and 51 to undergo surgery (including 
43 hysterectomies and 8 myomectomies). On the 
basis of results on the Medical Outcomes Study 
36-Item Short-Form General Health Survey ques-
tionnaire, they found no significant differences in 
the quality-of-life scores between the two groups 
at 1 year, although symptom scores were better in 
the surgical group at that follow-up assessment. 
Complication rates were similar at 1 year in the 
two groups, although the study was not powered 
to detect differences in these rates or to detect 
rare complications. Of note, complications gener-
ally occurred earlier in the surgical group (typi-
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on July 10, 2012. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
